Comparison 3. Angiotensin converting enzyme inhibitors versus placebo or no treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Cardiovascular mortality (RR)	2	945	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.61, 1.42]
2 Heart failure hospitalisation (RR)	3	1019	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.64, 1.15]
2.1 Follow‐up < 12 months	1	74	Risk Ratio (M‐H, Fixed, 95% CI)	0.42 [0.09, 2.04]
2.2 Follow‐up ≥ 12 months	2	945	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.66, 1.19]
3 Hyperkalaemia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 All‐cause mortality (RR)	4	1079	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.71, 1.38]
5 Quality of life (Minnesota)	2	154	Mean Difference (IV, Fixed, 95% CI)	‐0.09 [‐3.66, 3.48]
6 Withdrawal due to adverse event	3	1019	Risk Ratio (M‐H, Random, 95% CI)	1.53 [0.26, 9.00]